Treatment satisfaction of patients with psoriasis.
Treatment satisfaction of patients with psoriasis largely depends on the treatment modality, but evidence on preferences for specific medications is scarce. Here we assessed treatment satisfaction of 200 participants with moderate-to-severe psoriasis from a German University hospital with a 5-point scale and the Treatment Satisfaction Questionnaire for Medication (TSQM) and determined sociodemographic and disease-related influence factors. Participants obtaining biologicals and traditional systemic medications were significantly more satisfied than those receiving phototherapy or topical agents (TSQM = 323.3, 288.0, 260.6 or 266.8; p < 0.001). The highest TSQM score was calculated for ustekinumab (350.1), followed by acitretin (338.1), adalimumab (323.0), fumaric acid esters (304.7), infliximab (300.2), etanercept (298.8), and methotrexate (272.3; p < 0.001). High disease-related quality of life impairment (β = -0.437, p < 0.001) and psoriatic arthritis (β = -0.185, p = 0.005) were associated with decreased satisfaction. Optimising satisfaction is essential to improve adherence and outcome. We show high preferences for biologicals, particularly ustekinumab, but also good satisfaction with certain traditional medications.
Department of Dermatology, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany.
Marthe-Lisa
ML
Schaarschmidt
Christian
C
Kromer
Raphael
R
Herr
Astrid
A
Schmieder
Sergij
S
Goerdt
Wiebke K
WK
Peitsch
D000328:Adult; D000554:Ambulatory Care Facilities; D000704:Analysis of Variance; D001688:Biological Products / Q000627:therapeutic use*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003879:Dermatologic Agents / Q000627:therapeutic use; D005260:Female; D005858:Germany; D006785:Hospitals, University; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011701:PUVA Therapy / Q000379:methods; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D010778:Photochemotherapy / Q000379:methods; D011565:Psoriasis / Q000175:diagnosis* / Q000523:psychology / Q000628:therapy*; D011788:Quality of Life; D018570:Risk Assessment; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
D001688:Biological Products; D003879:Dermatologic Agents